IK-175 is under clinical development by Ikena Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IK-175’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IK-175 (KYN-175) is under development for the treatment of locally advanced or metastatic solid tumors including bladder cancer, recurrent head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer, ovarian cancer, colon cancer, pancreatic cancer and urothelial carcinoma. It is administered by oral route. The drug candidate acts by targeting aryl hydrocarbon receptor (AHR) through Indoleamine 2, 3-dioxygenase (IDO)/ tryptophan 2, 3-dioxygenase (TDO) pathway.
Ikena Oncology overview
Ikena Oncology, formerly Kyn Therapeutics is a health care provider. The company is advancing novel immunometabolic therapies for the treatment of cancers. Its pipeline development programs include EP4 antagonist IK-007, which promotes immune suppression across a diverse range of immune cells; AHR antagonist, prevent AHR-modulated tumor promotion; and IK-412, a kynurenine-degrading enzyme (Kynase) that targets implicated in immunosuppression across a range of tumor types through multiple immune cell effects. Its immunosuppressive pathway inhibits the IDO and TDO pathway, enabling the body’s immune system to attack the tumor. Ikena Oncology is headquartered in Boston, Massachusetts, the US.
For a complete picture of IK-175’s drug-specific PTSR and LoA scores, buy the report here.